AbbVie Inc. (NYSE:ABBV) shares are trading lower on Monday.
The U.S. drug maker shared topline results from a Phase 1 study of ABBV-295, a long-acting amylin analog aimed at treating obesity.
In March 2025, AbbVie and Gubra A/S announced a license agreement to develop GUB014295 (ABBV-295).
The stock’s performance comes as the broader market is experiencing some pressure, with the S&P 500 down 0.9% and the Healthcare sector losing 0.4%.
AbbVie’s Obesity Data
In the Phase 1 study, AbbVie reported that ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight, with mean percentage changes ranging from -7.75% to -9.79% at week 12.
The treatment was generally well tolerated, with mild gastrointestinal disorders being the most commonly reported adverse events.
The study involved various dosing regimens, with different doses tested between 2 mg and 14 mg.
The broader market is experiencing a mixed day, with the Healthcare sector currently ranked second among 11 sectors despite a slight decline of 0.43%.
AbbVie’s Technical Analysis
The stock is currently trading 0.4% above its 20-day simple moving average (SMA) and 1.5% above its 100-day SMA, indicating a degree of short-term strength.
Over the past 12 months, shares have increased by 6.06% and are positioned closer to their 52-week highs than lows, suggesting a bullish long-term trend.
The RSI is at 53.14, which is considered neutral territory, indicating no immediate overbought or oversold conditions. Meanwhile, the MACD is at 2.4702, above its signal line of 2.0809, suggesting bullish momentum in the stock.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that while there is some strength, traders should remain cautious.
- Key Resistance: $230.00
- Key Support: $220.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $241.24. Recent analyst moves include:
- RBC Capital: Initiated with Outperform (Target $260.00) (Feb. 25)
- Barclays: Initiated with Overweight (Target $275.00) (Feb. 20)
- Piper Sandler: Overweight (Raises Target to $299.00) (Feb. 18)
AbbVie’s Top ETF Exposure
- State Street Health Care Select Sector SPDR ETF (NYSE:XLV): 6.99% Weight
- The Health Care Select Sector SPDR Fund (NYSE:XLV): 8.28% Weight
- iShares US Healthcare ETF (NYSE:IYH): 6.57% Weight
ABBV Price Action: AbbVie shares were down 0.25% at $229.52 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
